GlassScriptPhysician profile
Paul Tran
NPI 1366806168
$7,844.33
in general payments reported to CMS, 2019-2025
8 companies · $3,986 in 2025
The $3,986 reported for 2025 was more than what 89% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $323 · 2023: $241 · 2024: $3,295 · 2025: $3,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,902 · Food and Beverage: $611 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,902.14 |
| Food and Beverage | $610.73 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoendo, INC | $5,269.11 | 2023-2025 | |
| Olympus Medical Systems Corporation | $2,000.00 | 2025 | Evis Exera II Ultrasound Gastrovideoscope |
| Olympus America INC. | $153.00 | 2022 | |
| Medtronic, INC. | $127.57 | 2024 | Digitrapper |
| Alcresta Therapeutics, INC. | $116.19 | 2025 | Relizorb |
| Abbvie INC. | $92.73 | 2022 | |
| Conmed Corporation | $77.17 | 2022 | |
| Travere Therapeutics, INC. | $8.56 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.